Login

Financial Snapshot

Revenue
TTM
$47.48M
Gross Margin
TTM
95.31%
Net Income
TTM
-$6.581M
Current Assets
2025 Q4
$44.40M
Current Liabilities
2025 Q4
$10.78M
Current Ratio
2025 Q4
411.77%
Total Assets
2025 Q4
$50.03M
Total Liabilities
2025 Q4
$10.89M
Book Value
2025 Q4
39.14M
Cash
Last 4 Quarters
N/A
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$9.433M

Stock Price

Loading...
Market Cap: $68.115 Million

About Biostem Technologies Inc

BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. Leveraging its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The firm's products include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AMERICAN AMNION. VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. VENDAJE is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE AC is a thicker structural tissue allograft composed of the amnion and chorion layer of the placental membrane. VENDAJE AC is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE OPTIC is a structural tissue allograft composed of the amnion layer of the placental membrane. The company also owns BioTissue's surgical and wound care business, including the Neox and Clarix product lines.

Industry: Biological Products, (No Diagnostic Substances) Peers: LeonaBio Inc Citius Pharmaceuticals Inc Eli Lilly and Co Eton Pharmaceuticals Inc Oramed Pharmaceuticals Inc MariMed Inc NGM BIOPHARMACEUTICALS INC Reviva Pharmaceuticals Holdings Inc

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support